Kornimate/medical-research-clean huggingface dataset:
evaluate the effect of dry needling on the temporomandibular joint in subjects who have suffered a whiplash as a result of a traffic accident

Conditions: Whiplash; Temporomandibular Joint Pain; Dry Needling Technique

Summary: the transportation industry is growing rapidly and the most popular mode is overland by road. traffic accidents are the most direct and serious risk to the lives of western people. a large number of traffic accidents occur on the roads each year, especially those caused by motor vehicles on motorways and urban ring roads, often resulting in massive loss of life. according to the world health organization (who), 1.35 million people die each year worldwide. whiplash is the most common injury in motor vehicle collisions, affecting 83% of injured people. the temporomandibular joint (tmj) is one of the most complex joints in the human body, since in addition to performing functions in dental occlusion, it does so in the neuromuscular system. due to the relationship of the neck with the mandible, the main objective of the study is to determine if there is an improvement in pain and functional limitation in general by applying the dry needling technique in the temporomandibular joint musculature.


Eligibility criteria:
inclusion criteria: * having suffered a traffic accident * having suffered a subsequent collision * having been diagnosed with whiplash in the hospital ''fundación jiménez díaz (fjd)´´ emergency room in the first 72 hours after the collision. * age between 18-45 years, to avoid osteoarthritis and other degenerative problems. * minimum 3 in temporomandibular joint (tmj) according to visual analog scale (vas) * consent to participate exclusion criteria: * temporomandibular joint (tmj) or craniofacial surgeries * spinal surgery * direct trauma in temporomandibular joint (tmj) or prior to the accident * botox, silicones or any type of cosmetic surgery in the facial region. * problems of migraines and tension headaches (pre-accident) * any degenerative musculoskeletal disease (fibromyalgia, rheumatoid arthritis, osteoarthritis) * fear of needles * any neurological disorder (trigeminal neuralgia, epilepsy) * pregnancy * uncontrolled vascular or metabolic problems
evaluation of mineral trioxide aggregates and grape seeds extract effect on pulpotomy

Conditions: Dental Caries

Summary: pediatric dentistry has always debated the benefits of vital pulp therapy. aim: the current study was done to differentiate the histo-pathological findings of mta versus grape seed extract in primary teeth undergoing pulpotomy as pulp dressing substances. materials and methods: according to the inclusion criteria, 16 primary teeth were selected in each group. randomly and equally, the teeth were split into two groups: (mta group) group i, and (gse group) group ii. after nine months, under a light microscope the teeth were evaluated and a clinical follow-up was conducted. periapical radiographs were also taken at this time.


Eligibility criteria:
inclusion criteria: * healthy patients with carious primary molars exclusion criteria: * root resorption
the safe prospective registry

Conditions: Atrial Fibrillation, Paroxysmal or Persistent

Summary: secretoneurin (sn) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. sn suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. sn is a novel biomarker that has shown the potential to predict adverse arrhythmic events.

the aim of the study is to sample sn before and after catheter ablation (ca) for atrial fibrillation (afib) to predict the recurrence after ca. also, the uric acid/albumin ratio will be assessed as a marker of afib recurrence. since the uric acid/albumin ratio has been shown to be predictive of afib in patients with myocardial infarction moreover incidence of atrial fibrillation is higher in patients with gout. as a side branch marker for silent brain injury, neuron-specific enolase (nse) and protein s100b will be evaluated. nse showed in small trials a significant increase after catheter ablation, as well as s100b. the prognostic power is not clear yet. from the systematic review, the most powerful predictors seem to be n-terminal (nt)-prohormone b-type natriuretic peptide (nt-pro-bnp/bnp), high-sensitivity c-reactive protein (hs-crp), interleukin-6 (il-6) and carboxy-terminal telopeptide of collagen type i. biomarkers are divided into 3 main types: congestion, inflammation, and renal function. patients will be enrolled before catheter ablation/electrical cardioversion for afib after signing is, and the blood sampling will be performed the day before and the day after catheter ablation. in the electric cardioversion arm, the blood sampling will be performed before electrical cardioversion and 2h after the cardioversion before discharge. patients will be followed for recurrency - all patients will have a 24-hour ecg holter and external loop recorder (mdt) for two weeks after the three months of the blanking period. clinical outpatient control will ensue in the 4th, eighth,12, and 24 months.

Eligibility criteria:
inclusion criteria: * atrial fibrillation (afib); (paroxysmal, persistent) * patients indicated for catheter ablation and/or electrical cardioversion * signed informed consent exclusion criteria: * longstanding or permanent atrial fibrillation * severe mitral regurgitation * heart failure with a permanently reduced ejection fraction * cerebral ischaemic stroke in \< 3 months * severe kidney injury * severe renal insufficiency * hepatic insufficiency limiting biomarker sampling * myocardial infarction \< 3 months

Keywords: atrial fibrillation secretoneurin catheter ablation electrical cardio version
comparison of the effects of lower limb immobilisation with cast and orthosis

Conditions: Venous Stasis; Deep Venous Thrombosis

Summary: in this study we are going to measure the blood flow in the lower limbs under cast immobilisation and also under mobilisation with an orthosis. the aim is to evaluate how the aforementioned modalities affect the blood flow and also to compare between the two.

background: lower limb immobilisation, for example after an achilles tendon rupture, is known to be a cause for dvt, partly due to blood stasis. vacoped is a weight-bearing orthosis with adjustable range of motion of the ankle which is used in our department in patients operated for achilles tendon rupture. aim: to assess the effects of a) lower leg casting in equinus without loading and b) application of the aforementioned orthosis with full weight baring in blood flow and microcirculation in the lower limbs. study plan: ten healthy individuals are planned to be recruited for this study. blood flow in the right popliteal will be measured with vein before, 30 and 60 min after the application of the cast or orthosis (alternate order between consequent individuals) with duplex ultrasound. the orthosis will be set to allow for ankle plantarflexion restricted between 15 and 30 degrees. tissue oxygen saturation in the lower limbs will also be measured using a somatic regional oxymetry modality, invos, with adhesive sensors applied on each leg above the soleus.

Eligibility criteria:
inclusion criteria: * healthy individuals exclusion criteria: * severe cardiovascular or renal disease causing pitting oedema * previous operation in the lower limbs affecting the vascular or lymphatic system * pregnancy

Keywords: cast orthosis immobilisation venous stasis circulation
qp/qs ratio by noninvasive methods in children with shunt dependent pulmonary circulation

Conditions: Anesthesia, General; Congenital Heart Disease; Blood Gas Monitoring, Transcutaneous; Blood Gas Analysis

Summary: in pediatric cardiac patients with shunt dependent pulmonary circulation, qp/qs ratio is a important parameter indicating the balance of pulmonaty and systemic circulation. this study will calculate qp/qs using variables measured using non-invasive monitors (cerebral oximeter and pulse oximeter). this value will be compared with qp/qs calculated using variables obtained from blood sample.

blood sampling will be performed in both arterial and central venous lines.

Eligibility criteria:
inclusion criteria: 1. pediatric cardiac patients scheduled to cardiac operation (shunt dependent pulmonary circulation) 2. preoperative spo2\<97% exclusion criteria: 1. unable to measure pulse oximeter or cerebral oximeter signal 2. unable to measure sao2 or smvo2 3. unstable vital sign

Keywords: qp/qs ratio pediatric congenital heart disease
cetuximab in combination with chemotherapy for patients with head and neck cancer

Conditions: Head and Neck Neoplasms

Summary: this is an open, multicenter phase ii study. the purpose is to demonstrate the efficacy of cetuximab in combination with carboplatin and vinorelbine as second line treatment in patients with recurrent or metastatic head and neck cancer who have progressed during or after treatment with first line cisplatinum.


Eligibility criteria:
inclusion criteria: * histologically verified squamous cell carcinoma of the head and neck where curatively intended local treatment is not possible. * measurable or non-measurable disease. * disease progression during or after first line palliative chemotherapy with cisplatinum or patients with recurrence \< 6 months after primary concomitant chemo-radiotherapy with cisplatinum. * who performance status 0-2. * age ≥ 18 years. * neutrophil count (anc) ≥ 1.5 x 10\^9/l and platelets ≥ 100 x 10\^9/l. * normal liver function with bilirubin \< 1.5 x unl (upper normal limit), no unl for alat with liver metastases. * creatinin clearance ≥ 50 ml/min. * signed informed consent. exclusion criteria: * other active malignant disease. * patients who are considered unable to follow the treatment plan or follow-up visits. * other serious disease (e.g. severe heart disease, myocardial infarction (mi) within 1 year, active infection). * any condition or treatment which after the opinion of the investigator may expose the patient to a risk or may influence the purpose of the trial. * pregnant or lactating women. * known hypersensitivity towards one or more of the components of the treatment. * prior treatment with either cetuximab or other inhibitors of egfr.

Keywords: platinum-resistent head and neck cancer cetuximab carboplatin navelbine phase ii trial combination chemotherapy
effect of three-stair-position on improvement of apnea of prematurity

Conditions: Apnea of Prematurity

Summary: the purpose of this study is evaluating the effectiveness of three-stair-position (tsp) on the rate of apnea of prematurity (aop), the feeding performance and the vital signs.

apnea of prematurity (aop) is common critical symptoms of preterm infants with great harm for prematurity. recurrent apnea may lead to brain damage caused by hypoxia, affecting the nervous system, even threatening life (1, 2). therefore, choosing an intervention which can prevent and reduce occurrence of aop with fewer side effects is an important issue that should be closely watched by neonatal intensive care unit (nicu) health care. prone position is the forefront treatment due to its simple, economic and non-invasive. in clinic, it includes horizontal prone position (hpp), head elevated tilt 15 ° prone position (hetp) and three-step-prone position (tsp)(3).many studies have shown that hetp can allow thoracic volume increased and make abdominal movement more coordinated in preterm children, and then it is more favorable than the hpp on improving respiratory function. so hetp has been a routine position in nicu instead of hpp (4, 5). hetp, however, always make the babies slide to the foot of the bed resulting in airway obstruction. therefore, scholars have proposed tsp which should prevent this phenomenon (6). in the study, the effectiveness of tsp on improvement of aop will be evaluated trying to find a more suitable position for preterm infants.

Eligibility criteria:
inclusion criteria: 1. preterm, gestational age(ga) \<34weeks determined by obstetric ultra-sonogram and clinical examination 2. steady vital signs 3. apgar scores were greater than or equal to 3 at 1min and greater than or equal to 5 at 5 minutes. exclusion criteria: 1. infants with congenital malformation，for example congenital heart disease, diaphragmatic hernia, hirschsprung,etc 2. infants who need special position and/or intervention (gastroschisis or umbilical catheterization) 3. weight\<1000g 4. infants who were undertaking conventional invasive mechanical ventilation.

Keywords: head elevated position preterm three-stair-position
a study to learn about effect of sisunatovir in healthy adult male participants

Conditions: Respiratory Syncytial Virus Infections

Summary: the purpose of this clinical trial is to learn about the safety, effects, and tolerability of the study medicine (sisunatovir). this study is looking for healthy adult participants who meet the following criteria: 1. males age 18 to 55 years 2. all fertile participants must agree to the use of highly effective contraception 3. body mass index (bmi) of 18 to 32.0 kg/m2; body weight of 55.0 to 100.0 kg. 4. participants who are overtly healthy as determined by medical evaluation. this includes medical history, physical examination, blood pressure, pulse rate, standard 12-lead ecg (electrocardiogram), and laboratory tests. this study will enroll up to 10 participants. all study participants will receive 1 dose of sisunatovir by mouth. the study duration is expected to be about 9 weeks. this includes a 28-day screening period, 16-day inpatient stay, and 2 overnight follow-up visits, if needed.


Eligibility criteria:
inclusion criteria (key): * males * age 18- 55 years * body mass index (bmi) 18.0 kg/m2 to 32.0 kg/m2 * body weight 55.0 kg to 100.0 kg * considered to be in good health * nonsmoker * content of 14c in urine, whole blood, and/or plasma samples does not exceed the general environmental background level of 14c exclusion criteria (key): * clinically significant abnormal medical history or any abnormal finding on physical examination, vital signs, ecg, laboratory tests * history of cancer that has not been in full remission for \>5 years * acute illness within 14 days prior to day 1 * history of significant drug allergies * history or presence of alcohol or drug abuse * recent history of incomplete bladder emptying with voiding or awakening more than once at night to void * usual habit of \ 3 bowel movements per day * exposure to radiation for therapeutic, diagnostic, or occupational reasons within the 12 months prior to day 1. * participation in another clinical study in which a \[14c\]-labeled drug was administered within 1 year prior to check-in * administration of another investigational medication within 60 days (or 5 half-lives, whichever is longer) prior to day 1 * participation in an investigational-device study within 60 days prior to day 1 * any ecg abnormality considered to be clinically significant by the investigator * qtcf interval \>450 msec and qrs interval \>120 msec * family history of long qt syndrome or of unexplained sudden death in a first-degree relative under 50 years of age * documented congenital or acquired long qt syndrome * presence of clinically significant hypertension * presence of clinically significant hypotension * loss or donation of more than 500 ml blood within 60 days prior to the screening * excessive consumption of alcohol * use of any live vaccinations within 30 days * use/consumption of food or drugs known to be moderate or strong cytochrome p450 3a4 (cyp3a4) inducers or potent cyp3a4 inhibitors within 14 days or 5 half-lives, whichever is longer, prior to rv521 administration
cardiometabolic effects of aerobic exercise plus breaking sitting

Conditions: Sedentary Behaviour; Sedentary Time

Summary: the goal of this randomized crossover clinical trial is to investigate the effects of interrupting prolonged sitting with intermittent walks of equal volume but at different frequencies, in addition to moderate-intensity aerobic exercise, on postprandial serum lipid profile in young adults between the ages of 18-30. the main questions it aims to answer are: * do interrupting prolonged sitting with intermittent walks of equal volume but at different frequencies sustain positive cardiometabolic effects after moderate-intensity aerobic exercise? * if "yes", which frequency of breaks is more effective to provide cardiometabolic benefits? participants will complete four conditions on separate days: 1) 6.5 hours of prolonged sitting after 30 minutes of moderate intensity aerobic exercise 2) breaking prolonged sitting with 2 minutes of walking every 30 minutes after 30 minutes of moderate intensity exercise 3) breaking prolonged sitting with 4 minutes of walking every 1-h after 30 minutes of moderate intensity exercise 4) breaking prolonged sitting with 8 minutes of walking every 2-h after 30 minutes of moderate intensity aerobic exercise.


Eligibility criteria:
inclusion criteria: * being between the ages of 18-30 * being able to participate in physical activity * more than 7 hours of daily sitting time measured subjectively * not exercising regularly in the last 3 months exclusion criteria: * hypertension * coronary heart disease * heart failure * diabetes mellitus * metabolic syndrome * obesity * hypothyroidism * non-alcoholic fatty liver disease * chronic inflammatory joint disease * chronic renal failure * cushing's syndrome * hiv infection * being on antihypertensive medication * being on lipid-lowering medication * being on antidiabetic medication * being on systemic glucocorticoid medication * ldl-cholesterol≥130 mg.dl-1 * hdl-cholesterol \<40 mg.dl-1 for men; \<50 mg.dl-1 for women * prediabetes * alcohol addiction * smoking * pregnancy

Keywords: sedentary break prolonged sitting blood lipids blood pressure aerobic exercise walking
effect of labetalol, atenolol, and nifedipine on maternal hemodynamics measured by icg in early pregnancy

Conditions: Systolic Hypertension; Pregnancy Related; Diastolic Hypertension; Cardiac Output, Low; Cardiac Output, High

Summary: the purpose of the research is to characterize the effect of labetalol, atenolol, and nifedipine on maternal hemodynamics early in pregnancy. patients will be given medication based on their hemodynamics and asked to return for a repeat measurement.

when a patient presents to the maternal hypertension center at cabell huntington hospital, she will receive a non-invasive hemodynamic assessment via the nicas system as per usual protocol. the nicas system uses impedance cardiography which provides a reliable assessment of cardiovascular, respiratory, and fluid parameters. in typical practice, the vasodilator nifedipine is initiated for increased systemic vascular resistance and elevated cardiac output is treated with beta blockade (via either atenolol or labetalol). the medication to be given to each subject will be based on their hemodynamics. specifically, nifedipine will be given for a mean arterial pressure \>100 and a beta blocker will be given for a cardiac output \>8 l/min. the patients will be asked to return in one week for repeat icg measurement.

Eligibility criteria:
inclusion criteria: * patients presenting to maternal hypertension center at cabell huntington hospital * english speaking * 18-45 years old. * willing to provide informed consent * gestational age prior to 15 weeks gestation exclusion criteria: * non-english speaking patients, patients * \ 45 years old * not willing or able to provide consent * gestational age \>15 weeks
a study of the effectiveness of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia (aml) ineligible for intensive chemotherapy

Conditions: Acute Myeloid Leukemia (AML); Cancer

Summary: a study evaluating the effectiveness and safety of venetoclax, in combination with azacitidine or decitabine, in an outpatient setting for treatment-naïve participants with aml who are ineligible for intensive chemotherapy.


Eligibility criteria:
inclusion criteria: * participant has confirmation of acute myeloid leukemia (aml) by world health organization (who) criteria * participant is deemed by the investigator to be an appropriate candidate for outpatient ramp-up of venetoclax * participant is not eligible to receive treatment with standard cytarabine and anthracycline induction regimens * participant has not received prior treatment for aml (treatment naïve) with the exception of hydroxyurea * participant has no evidence of spontaneous tumor lysis syndrome (tls) at screening * participant can have progressed from myelodysplastic syndrome (mds) or be considered to have secondary aml and could have been treated with growth factors or other agents with the exception of hypomethylating agents * participant has adequate kidney, liver, and hematology laboratory values as detailed in the protocol * has an eastern cooperative oncology group (ecog) performance status of 0 to 3 exclusion criteria: has a history of the following conditions: * acute promyelocytic leukemia * known active central nervous system involvement with aml * positive for hiv (hiv testing is not required) * positive for hepatitis b or c infection with the exception of those with an undetectable viral load within 3 months * cardiovascular disability status of new york heart association class \> 2 * chronic respiratory disease that requires continuous oxygen or any other medical condition that in the opinion of the investigator would adversely affect his/her participating in this study * malabsorption syndrome or other condition that precludes enteral route of administration has a history of other malignancies within 2 years prior to study entry, with the exception of: * adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast * basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin * previous malignancy confined and surgically resected (or treated with other modalities) with curative intent

Keywords: acute myeloid leukemia (aml) cancer treatment-naïve venetoclax azacitidine decitabine outpatient setting
high protein and energy diet for better coughing in copd patients

Conditions: Copd

Summary: chronic obstructive lung disease (copd) is one of the leading death causes worldwide. copd is a disease that is characterized by chronic inflammation which leads to irreversible damage of airways and lung tissue. this intervention investigates the effects of a diet high in protein and energy for the improvement of coughing capacity and lung function of copd patients. the patients will be recruited as part of a lung rehabilitating programme which takes place in bispebjerg and hvidovre hospital. the intervention group receives individual nutritional guidelines whereas the control group continues their usual diet. blood tests will be performed at baseline and the end of the study. other anthropometric measures include spirometry for lung function, hand grip strength and fat free mass to assess muscle waisting.

40 patients with copd randomized to diet with protein 1.3 g/kg/day or habitual intake: primary endpoint (before-after): leicester cough questionnaire secondary endpoints: adl-score, no. daily cough periods, development in fev1 and fvc, hand-grib-strenght, use of respiratory medications, smoking, appetite, admissions to hospital, antibiotics and/or steroids, oxygen saturation, ffm (bia), coughs tests in spirometer and peak-flow-meter study period: 2 months

Eligibility criteria:
inclusion criteria: * diagnosed with copd * participating in ongoing lung rehabilitating programme at hvidovre and bispebjerg hospital * over 18 years exclusion criteria: * plasma creatinin over 200 mikrog/l * dementia * unable to read or speak danish